Member Directory

Opthea Limited


Member Contact: Megan Baldwin

Position: CEO & Managing Director

Industry: Biotech & Pharmaceuticals

Company Profile:

Opthea Limited (ASX:OPT) is a clinical stage biotechnology company based in Melbourne Australia developing novel therapies for the treatment of eye diseases.

Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet age-related macular degeneration (wet AMD).

Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients.

Enquiries can be directed to:


News & opinion

Member Directory